5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Adverse Immune Signatures and their Prevention in Corneal Transplantation (VISICORT)
Date du début: 1 avr. 2014, Date de fin: 31 mars 2019,
"Immune system response is the most complex barrier to long-term success of tissue transplants/implants from allogeneic and bio-artificial sources. While newly developed tissue transplant procedures are not yet performed frequently enough for robust analysis of adverse immune responses in humans, corneal transplantation (CT) is a well-established allogeneic tissue transplant with >100,000 full- an ...
Voir le projet
12
Participants partenaires
TERMINÉ
Universal Influenza Vaccines Secured (UNISEC)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
UNISEC brings together a European consortium of 3 University partners, 5 National Health Institutes and 3 SMEs, all with leading expertise in influenza vaccine research and development, to work on promising recently developed concepts for a universal influenza vaccine. The consortium is exceptionally strong, interdisciplinary and intersectional in nature, and encompasses a unique combination of sc ...
Voir le projet
15
Participants partenaires
TERMINÉ
Integration of Biology and Engineering into an Economical and Energy-Efficient 2G Bioethanol Biorefinery (PROETHANOL2G)
Date du début: 1 nov. 2010, Date de fin: 31 oct. 2014,
The European Union has set a 10 % mandatory target for the share of renewables (including biofuels) in transportation sector by 2020 in Europe.To achieve this goal sustainable biofuels from lignocellulosic biomass must deploy in Europe very soon since the competition between food vs. energy prevents further (significant) increase on the current first-generation biofuels already in the market. This ...
Voir le projet
10
Participants partenaires
TERMINÉ
Prediction of bladder cancer disease course using risk scores that combine molecular and clinical risk factors (UROMOL)
Date du début: 1 févr. 2008, Date de fin: 31 juil. 2013,
"Bladder cancer is a recurrent and very prevalent cancer and it generates the highest cost per patient in Europe. New genomic methods have allowed identifying new markers with potential clinical application. However, due to the use of single-marker assays and poor study design, none of these markers has made it to the clinic. FGFR3 and PIK3CA mutations, expression profiles, and microsatellite alte ...
Voir le projet
8
Participants partenaires
TERMINÉ
Genomic Instability in Cancer and Precancer (GENICA)
Date du début: 1 janv. 2008, Date de fin: 31 déc. 2010,
"Genomic instability is a characteristic of practically all human cancers. Recent results generated by members of this Consortium suggest that signs of genomic instability are evident from the very beginning of human cancer development, even in precancerous lesions. In these early lesions, the genomic instability affects primarily specific genomic loci, called common fragile sites. Because common ...
Voir le projet